LabyrinthitisMANAGEMENT

ENT AND MAXILLOFACIAL PRESENTATIONS · 12 SECTIONS

⚲

487 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Acute laryngitis Acute pharyngitis Auricular hematoma Bezold's Abscess Cerumen impaction Dry socket Ear foreign body Epistaxis (anterior)Epistaxis (Posterior)Labyrinthitis Ludwig's Angina Malignant Otitis Externa Marcus Gunn Pupil Mastoiditis Meniere's Disease Nasal Bone Fracture Nasal foreign body Nasal Septal Hematoma Otitis externa Otitis Media Post-tonsillectomy hemorrhage Sialolithiasis and sialadenitis Sinusitis Sudden Sensorineural Hearing Loss TMJ dislocation Tympanic membrane perforation Vestibular Neuronitis

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp29

Immediate priorities

›Stroke exclusion — the cannot-miss diagnosis in acute vestibular syndrome (AVS)

›AVS defined as continuous vertigo >24 hours with spontaneous nystagmus

›Up to 25% of ED AVS presentations are posterior circulation stroke

›New acute hearing loss with AVS is more likely stroke than labyrinthitis per GRACE-3

›Immediate neurology/stroke activation if HINTS exam is abnormal

›Airway and hydration threats

›Intractable vomiting with dehydration

›IV access and fluid resuscitation if hemodynamically compromised

›Antiemetic therapy to control vomiting and allow PO tolerance

›Bacterial labyrinthitis recognition

›Fever plus otalgia plus otorrhea indicates otogenic source

›Meningeal signs indicate meningogenic spread

›Immediate IV antibiotics and ENT consultation if bacterial etiology suspected

Monitoring and targets

›Monitoring bundle

›Vital signs including temperature — fever suggests bacterial etiology

›Blood pressure — hypertension raises stroke concern

›Orthostatic vitals if dehydration suspected

›Neurologic status trend every 30–60 minutes

›Escalation triggers

›Normal head impulse test (HIT) in AVS — central cause until proven otherwise

›Direction-changing or purely vertical nystagmus — immediate stroke workup

›Skew deviation on test of skew — central cause

›Severe truncal ataxia — inability to sit unsupported suggests posterior fossa stroke

›New focal neurologic deficit — dysarthria, diplopia, facial droop, limb weakness

Key consults

›Consultation triggers

02History/hx45

Presenting symptoms

›Core AVS symptom complex

›Acute onset severe continuous rotational vertigo

›Onset over hours, persisting beyond 24 hours

›Not episodic and not positionally triggered

›Nausea and vomiting

›Aural fullness

›Gait unsteadiness veering toward affected side

›Hearing involvement — defining feature of labyrinthitis versus vestibular neuritis

›Unilateral sensorineural hearing loss

›Tinnitus ipsilateral to affected ear

›Symptom onset timing relative to vertigo

Risk factors and antecedents

›Viral prodrome

›Recent upper respiratory tract infection (most common antecedent)

›Herpes family reactivation — HSV-1, VZV, HHV-6/7

›COVID-19 infection or post-acute sequelae

›Bacterial and structural risk

›Acute or chronic otitis media

›Cholesteatoma with bony erosion into labyrinth

›Recent bacterial meningitis (meningogenic labyrinthitis)

›Ear surgery or trauma

›Vascular and stroke risk

›Hypertension, diabetes mellitus, atrial fibrillation

›Hyperlipidemia, smoking, age >50

›Prior TIA or stroke

›Other medical history

›Immunosuppression or immunocompromised state

03Physical Exam/exam45

Vital signs

›Vital sign assessment

›Temperature — fever suggests bacterial labyrinthitis

›Blood pressure — hypertension raises stroke risk

›Heart rate and rhythm — atrial fibrillation as cardioembolic risk

›Oxygen saturation — respiratory compensation

Otoscopic exam

›Ear canal and tympanic membrane

›Otitis media — erythema, effusion, perforation

›Cholesteatoma — keratin debris, marginal perforation

›Otorrhea or discharge character

›Tympanic membrane mobility with pneumatic otoscopy

Bedside hearing assessment

›Tuning fork and voice tests

›Finger rub or whispered voice unilateral comparison

›Weber test — lateralizes away from sensorineural-affected ear

›Rinne test — air conduction greater than bone conduction in sensorineural loss

HINTS exam — cornerstone for AVS triage

›Head impulse test (HIT)

›Positive HIT (corrective saccade toward affected side) — peripheral pattern, consistent with labyrinthitis

›Normal HIT in AVS — central cause until proven otherwise

›Sensitivity for central cause 93% when combined with nystagmus and skew assessment

›Nystagmus character

›Unidirectional horizontal-torsional nystagmus beating away from affected ear — peripheral

›Suppression with visual fixation — peripheral pattern

›Direction-changing nystagmus — central cause

›Purely vertical or purely torsional nystagmus — central cause

›Test of skew

04Differential Diagnosis/ddx42

Central causes — cannot-miss

›Posterior circulation stroke — most critical mimic

›Cerebellar infarction or brainstem infarction

›AICA territory infarction — sudden vertigo plus hearing loss plus other brainstem signs

›ICD-10: I63.x (Cerebral infarction)

›Up to 25% of ED AVS presentations; more likely than labyrinthitis when hearing loss is new

›Posterior fossa hemorrhage

›Severe headache, rapid neurologic deterioration

›ICD-10: I61.x (Intracerebral hemorrhage)

›Multiple sclerosis demyelinating plaque

›Young patient, prior episodes, INO on exam

›ICD-10: G35

Peripheral vestibular — main differential

›Vestibular neuritis

›Identical presentation but no hearing loss

›ICD-10: H81.23 (Vestibular neuronitis)

›Benign paroxysmal positional vertigo (BPPV)

›Episodic, brief (<1 minute), triggered by head position change

›Positive Dix-Hallpike — should be negative in labyrinthitis

›ICD-10: H81.1x

›Meniere disease

›Episodic 20 minutes to 12 hours, fluctuating hearing loss, tinnitus, aural fullness

›Not continuous beyond 24 hours

›ICD-10: H81.0x

›Vestibular migraine

›Episodic, migraine headache history, hearing loss less common

›ICD-10: G43.A0

›Perilymph fistula

05Laboratory Tests/lt35

Routine labs

›Standard labs — generally not required for uncomplicated viral labyrinthitis

›Targeted use based on clinical suspicion of bacterial or systemic cause

›GRACE-3 supports selective lab ordering

Infectious workup

›Complete blood count with differential

›Leukocytosis suggests bacterial etiology

›Indication: fever, otalgia, otorrhea, or systemic toxicity

›C-reactive protein and ESR

›Elevated in bacterial labyrinthitis and autoimmune inner ear disease

›Useful to monitor treatment response

›Blood cultures

›Two sets before antibiotics if bacteremic labyrinthitis suspected

›Indication: fever, hemodynamic instability, meningeal signs

›Lumbar puncture

›CSF analysis if meningitis or meningogenic labyrinthitis suspected

›CSF glucose, protein, cell count, gram stain, culture

Metabolic and vascular workup

›Glucose and HbA1c

›Diabetes is a major vascular risk factor for posterior circulation stroke

›Order if vascular risk factors present

›Lipid panel

›Hyperlipidemia as stroke risk modifier

›Renal and hepatic panel

›Guides drug dosing if treatment initiated

Targeted autoimmune and serologic labs

›Autoimmune panel for atypical or bilateral cases

›ANA, anti-dsDNA for systemic autoimmune disease

06Diagnostic Tests/dt53

Scoring Systems

›HINTS exam — primary decision tool for AVS triage

›Head Impulse test, Nystagmus pattern, Test of Skew

›Sensitivity 93%, specificity 83% for central cause when performed by trained clinicians

›HINTS Plus adds hearing assessment — sensitivity approaches 99%

›GRACE-3 Level B recommendation: HINTS Plus by trained clinician

›Cochrane review (Gottlieb 2023) confirms diagnostic accuracy

›STANDING algorithm

›SponTAneous Nystagmus, Direction, Inner ear, New neurological symptoms/General

›Gerlier 2021: sensitivity 93%, specificity 84% for central versus peripheral AVS in ED

›Alternative to HINTS when HIT difficult to perform

›ABCD2 score

›Predicts short-term stroke risk after TIA — limited specificity in isolated dizziness

›Score >=4 raises concern for central cause in AVS context

›Dix-Hallpike maneuver

›Should be negative in labyrinthitis

›Positive result — brief geotropic nystagmus — indicates BPPV and redirects diagnosis

MRI

›MRI brain with diffusion-weighted imaging (DWI)

›Gold standard for posterior fossa stroke detection

›Indications: abnormal HINTS, focal neurologic signs, high vascular risk, sudden onset

›ACR Appropriateness Criteria: MRI with DWI appropriate for acute dizziness with neurologic symptoms

›Critical limitation: DWI false-negative rate up to 20% in first 24–48 hours for posterior fossa stroke

›Repeat MRI at 48–72 hours if initial DWI negative and clinical suspicion remains high

›MRI with gadolinium — labyrinthine enhancement

›3D FLAIR sequence can demonstrate labyrinthine enhancement in viral or bacterial labyrinthitis

›Useful for confirming diagnosis when clinical picture atypical

›Enhancement pattern: cochlear and vestibular labyrinth

07Disposition/dispo25

Discharge criteria

›Safe discharge parameters

›Confident peripheral diagnosis established — positive HIT, unidirectional nystagmus, no skew, no focal neurologic deficits

›Symptoms manageable with oral medications

›Able to tolerate PO fluids

›Able to ambulate safely with or without assistance

›Reliable follow-up arranged with ENT/audiology within 1–2 weeks

›Vestibular rehabilitation therapy referral placed

›Responsible adult at home for first 24–48 hours

Admission criteria

›Indications for hospital admission

›Suspected or confirmed posterior circulation stroke — stroke unit

›Suspected bacterial labyrinthitis — IV antibiotics required

›Meningeal signs — immediate LP and neurology

›Intractable vomiting with dehydration unresponsive to ED antiemetics

›Inability to ambulate safely — especially elderly or those living alone

›Immunocompromised patient with atypical labyrinthitis

›Intracranial complication — epidural abscess, brain abscess, subdural empyema

Transfer criteria

›Transfer triggers

›Posterior circulation stroke without neurology or stroke unit capability

›Surgical intracranial complication requiring neurosurgical intervention

›Bacterial labyrinthitis with cholesteatoma requiring operative ENT

Follow-up planning

›Outpatient follow-up timeline

›ENT/audiology within 1–2 weeks — formal audiometry and vestibular assessment

›Primary care within 1 week for vascular risk factor optimization

›Vestibular rehabilitation therapy initiation within 1–2 weeks

08Treatment/t65

Immediate stabilization

›Supportive initial care

›IV access for parenteral antiemetics and fluid replacement

›IV normal saline 500 mL bolus if dehydrated

›Nothing by mouth until vomiting controlled

›Bed rest with fall prevention in acute phase

Antiemetics

›Ondansetron

›4 mg IV or ODT every 6–8 hours as needed

›First-line for nausea and vomiting

›Safe across adult age groups

›Monitor QTc at high doses

›Promethazine

›12.5–25 mg IV or IM every 6 hours as needed

›Avoid in elderly — sedation and anticholinergic effects (Beers Criteria)

›Alternative to ondansetron when IV access unavailable

›Metoclopramide

›10 mg IV every 8 hours

›Dopamine antagonist with prokinetic effect

›Avoid in Parkinson disease

Vestibular suppressants — limit to 3 to 5 days maximum

›Meclizine

›12.5–25 mg PO every 8 hours as needed

›First-line oral vestibular suppressant for outpatient use

›Avoid in elderly patients — AGS Beers Criteria anticholinergic risk

›Limit duration to 3–5 days — prolonged use inhibits central compensation and delays recovery

›Dimenhydrinate

›25–50 mg PO or IV every 6 hours as needed

›Suitable for parenteral use in severe acute vomiting

›Same duration caution as meclizine

›Diphenhydramine

›25–50 mg PO or IV every 6 hours as needed

›Alternative when dimenhydrinate unavailable

›Benzodiazepines — short-term only for severe symptoms

›Diazepam 2–5 mg PO or IV every 8 hours

›Lorazepam 0.5–1 mg PO or IV every 8 hours

›Maximum 2–3 days use — risk of dependence and prolonged central compensation delay

›Avoid in elderly and respiratory compromise

Corticosteroids — shared decision-making

›Methylprednisolone taper protocol

›100 mg daily tapering over 3 weeks

›Evidence from vestibular neuritis trials — Fishman Cochrane 2011 showed modest benefit

›Evidence base for labyrinthitis is extrapolated — GRACE-3 recommends shared decision-making

›Discuss risks: hyperglycemia, insomnia, mood disturbance

›Prednisone alternative

›1 mg/kg/day (maximum 60 mg) for 5 days then taper over 10–14 days

›Monitor blood glucose — especially in diabetic patients

›Counsel on typical side-effect profile

Antiviral therapy

›Antivirals not recommended for viral labyrinthitis

›No evidence of benefit — GRACE-3 Level C: antivirals not recommended

›Exception: Ramsay Hunt syndrome (herpes zoster oticus)

›Valacyclovir 1000 mg PO three times daily for 7 days for Ramsay Hunt

›Prednisolone 1 mg/kg/day concurrent with antiviral for Ramsay Hunt

Antibiotics — bacterial labyrinthitis

›Otogenic bacterial labyrinthitis

›Ceftriaxone 2 g IV every 24 hours

›Add vancomycin 15–20 mg/kg IV every 8–12 hours if MRSA or penicillin-allergic

›ENT consultation for possible surgical drainage, mastoidectomy, or tympanostomy

›Duration: minimum 14 days for complicated otitis with labyrinthitis

›Meningogenic bacterial labyrinthitis

›Treat underlying meningitis — ceftriaxone 2 g IV every 12 hours

›Add dexamethasone 0.15 mg/kg IV every 6 hours for 4 days — reduces hearing loss risk in bacterial meningitis

›Dexamethasone most effective when given before or with first antibiotic dose

Vestibular rehabilitation therapy

›Vestibular rehabilitation — cornerstone of long-term recovery

›Supported by systematic review evidence

›Gaze stabilization exercises — promote central compensation

›Canalith repositioning maneuvers if secondary BPPV develops

›Balance retraining and habituation exercises

›Referral at time of ED discharge

›Initiation within 1–2 weeks of symptom onset

09Special Populations/sp53

Pregnancy

›Physiologic considerations

›Nausea and vomiting of pregnancy may complicate symptom interpretation

›Pre-eclampsia and eclampsia can cause dizziness and must be excluded in third trimester

›Hyperemesis gravidarum complicates fluid management

›Medication safety in pregnancy

›Ondansetron — Category B; use with caution especially first trimester (possible cardiac defect signal)

›Dimenhydrinate — Category B; generally considered safe in second and third trimester

›Meclizine — Category B; commonly used for nausea in pregnancy

›Benzodiazepines — avoid; associated with cleft palate and neonatal withdrawal

›Corticosteroids — generally Category C; short course acceptable if significant benefit

›Promethazine — Category C; fetal respiratory depression risk near term

›MRI safety in pregnancy

›MRI without gadolinium generally safe at any gestational age

›Gadolinium crosses placenta — avoid unless essential

›CT temporal bone delivers radiation — minimize; shield abdomen if required

›Stroke risk in pregnancy

›Hypercoagulable state of pregnancy increases posterior circulation stroke risk

›Peripartum cardiomyopathy as cardioembolic source

›Higher clinical threshold for MRI DWI in pregnant patient with AVS

Geriatric

›Age-related considerations

›Falls risk markedly elevated — vertigo plus baseline gait instability

›Higher prevalence of vascular comorbidities — stroke must be assumed until excluded

›Central compensation is slower and less complete in elderly patients

›Polypharmacy review — vestibulotoxic medications, antihypertensives causing orthostasis

›Medication modifications in elderly

›Avoid meclizine and diphenhydramine — AGS Beers Criteria anticholinergic risk

10Background/b44

Epidemiology

›Incidence and prevalence

›Labyrinthitis accounts for a minority of AVS presentations — vestibular neuritis is more common

›Viral labyrinthitis most common form — peaks in spring and early summer consistent with viral URI seasonality

›Peak age of incidence 30–60 years

›Slight female predominance in viral labyrinthitis

›Bacterial meningitis leading cause of meningogenic labyrinthitis — now rare with H. influenzae B vaccination

›Morbidity and outcomes

›Vertigo typically resolves over days to weeks with central compensation

›Hearing loss may be permanent — varies by severity and etiology

›Bacterial labyrinthitis carries higher rate of permanent profound sensorineural hearing loss

›Risk of secondary BPPV as sequela — free-floating otoconia from damaged utricle

›Up to 30% of patients report persistent chronic imbalance

Pathophysiology

›Viral labyrinthitis mechanism

›Inflammatory invasion of membranous labyrinth — cochlea and vestibular apparatus simultaneously affected

›Most common viruses: HSV-1, VZV, CMV, mumps, influenza, COVID-19

›Zhao 2023: HSV-1 induces inflammatory cascade in spiral ganglion neurons and vestibular cells

›Neuronal degeneration leads to permanent hearing loss and incomplete vestibular recovery

›HHV-6 and HHV-7 reactivation implicated — El-Hussein 2020 case series

›Bacterial labyrinthitis mechanisms

›Otogenic: direct spread from middle ear via round window membrane or bony erosion from cholesteatoma

›Meningogenic: retrograde spread from subarachnoid space via cochlear aqueduct — most common route

›Pathology: suppurative inflammation, endolymph and perilymph invasion, labyrinthitis ossificans as sequela

›Wiedermann 1986: H. influenzae meningitis model — perilymphatic infection precedes ossification

›Vestibular compensation

›Central vestibular compensation mediated by cerebellum and brainstem

›Static symptoms (spontaneous nystagmus, skew) resolve first — days to weeks

11Patient Discharge Instructions/pdi28

copy discharge instructions

›Diagnosis and expected course

›You have been diagnosed with labyrinthitis — an inflammation of the inner ear causing dizziness and hearing changes

›Dizziness and spinning sensation typically improves significantly over the first 3–7 days

›Mild imbalance may persist for several weeks to months

›Hearing loss, if present, may be permanent — follow-up with a hearing specialist is essential

›Medications prescribed

›Take your prescribed anti-nausea medication only as needed for severe symptoms

›Stop vestibular suppressant medications after 3–5 days even if mild dizziness persists — stopping these medications helps your brain adapt and speeds your recovery

›Do not take meclizine or dimenhydrinate for longer than 5 days without medical advice

›Take any prescribed steroid exactly as directed and do not stop early without consulting your doctor

›Activity restrictions

›Do not drive until dizziness has completely resolved

›Do not operate heavy machinery or work at heights

›Move slowly when changing positions to reduce fall risk

›Use handrails on stairs and remove loose rugs or trip hazards at home

›Have someone with you for the first 24–48 hours

›Follow-up appointments

›Ear, nose, and throat specialist or audiologist within 1–2 weeks for a hearing test

›Family doctor within 1 week for symptom reassessment

›Vestibular physiotherapy referral — exercises to help your brain compensate for inner ear damage

›Return to emergency department immediately if

›New slurred speech, facial drooping, arm or leg weakness or numbness

›Sudden severe headache unlike any before

›Double vision or sudden vision changes

›Dizziness suddenly worsens after initial improvement

›High fever, severe ear pain, or neck stiffness

›Unable to keep fluids down after taking anti-nausea medication

12References/r23

Guidelines and key sources

›GRACE-3 — Edlow JA et al. Guidelines for Reasonable and Appropriate Care in the Emergency Department 3 (GRACE-3): Acute Dizziness and Vertigo in the Emergency Department. Academic Emergency Medicine 2023

›Primary source for HINTS exam evidence, steroid recommendations, antiviral guidance, and vestibular suppressant duration limits

›Level B recommendation for HINTS Plus by trained clinicians

›Fishman JM, Burgess C, Waddell A. Corticosteroids for the Treatment of Idiopathic Acute Vestibular Dysfunction (Vestibular Neuritis). Cochrane Database of Systematic Reviews 2011

›Modest short-term benefit of corticosteroids; evidence extrapolated to labyrinthitis

›Gottlieb M, Peksa GD, Carlson JN. Head Impulse, Nystagmus, and Test of Skew Examination for Diagnosing Central Causes of Acute Vestibular Syndrome. Cochrane Database of Systematic Reviews 2023

›Diagnostic accuracy of HINTS: sensitivity 93%, specificity 83%

›Wang LL et al. ACR Appropriateness Criteria: Dizziness and Ataxia 2023 Update. Journal of the American College of Radiology 2024

›MRI DWI appropriate for neurologic dizziness; CT head low-yield for posterior fossa stroke

›Shah VP et al. Diagnostic Accuracy of Physical Examination in ED Patients with Acute Vertigo or Dizziness: Systematic Review and Meta-Analysis for GRACE-3. Academic Emergency Medicine 2023

›HINTS Plus sensitivity approaches 99%

›Gerlier C et al. Differentiating Central From Peripheral Causes of Acute Vertigo in an Emergency Setting with HINTS, STANDING, and ABCD2. Academic Emergency Medicine 2021

›STANDING algorithm: sensitivity 93%, specificity 84%

›Hydén D, Akerlind B, Peebo M. Inner Ear and Facial Nerve Complications of Acute Otitis Media. Acta Oto-Laryngologica 2006

›Bacteriology and virology of otogenic labyrinthitis

›Beyea JA, Agrawal SK, Parnes LS. Recent Advances in Viral Inner Ear Disorders. Current Opinion in Otolaryngology and Head and Neck Surgery 2012

›Viral etiology, HSV and VZV involvement in labyrinthitis

›Zhao Z et al. Cellular Processes Induced by HSV-1 Infections in Vestibular Neuritis. Viruses 2023

›Mechanism of HSV-1 in vestibular ganglion damage

›Baloh RW. Vestibular Neuritis. New England Journal of Medicine 2003

›Classic reference for AVS, vestibular neuritis and labyrinthitis pathophysiology

›Aykul Yagcioglu A, Ertugrul G. Sudden Unilateral Hearing Loss and Acute Vestibular Syndrome. Journal of the American Academy of Audiology 2025

›Case illustrating pediatric labyrinthitis presentation and audiometric findings

Learn More: Labyrinthitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.